X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. (r)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclohexanecarboxaldehyde, 21-isobutyrate
2. Alvesco
3. Omnaris
1. Alvesco
2. Omnaris
3. 126544-47-6
4. Zetonna
5. Rpr251526
6. Rpr-251526
7. Ciclesonide [inn]
8. 141845-82-1
9. Bi54903
10. S59502j185
11. [2-[(1s,2s,4r,6r,8s,9s,11s,12s,13r)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
12. [2-[(1s,2s,4r,8s,9s,11s,12s,13r)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
13. Osonase
14. Osonide
15. Omnair
16. Rpr 251526
17. Alvesco Hfa
18. Omnaris Hfa
19. Alvesco (tn)
20. Omnaris (tn)
21. Ciclesonide [usan:inn]
22. Btr-15k
23. Ciclesonide (jan/usan/inn)
24. Btr-15
25. Tbn-15
26. (r)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclohexanecarboxaldehyde, 21-isobutyrate
27. Unii-s59502j185
28. Ncgc00167484-01
29. (11?,16?)-16,17-[[(r)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione
30. Alvesco 80
31. Zetonna (tn)
32. Alvesco, Ciclesonide
33. Byk-20426
34. Alvesco 160
35. By-9010
36. Ks-1165
37. Ac1miwnr
38. Ciclesonide [mi]
39. Ciclesonide [jan]
40. Ciclesonide [usan]
41. Ciclesonide [vandf]
42. Schembl3688
43. Ciclesonide [mart.]
44. Dsstox_cid_26659
45. Dsstox_rid_81802
46. Dsstox_gsid_46659
47. Ciclesonide [who-dd]
48. B-9207-015
49. Gtpl7469
50. El-87-6
51. Chembl2040682
52. Dtxsid9046659
53. Chebi:31397
54. Ciclesonide, >=98% (hplc)
55. Ciclesonide [orange Book]
56. Ciclesonide [ep Monograph]
57. Hms3714n07
58. Ex-a4195
59. Hy-b0625
60. Zinc3915154
61. Tox21_112486
62. Bdbm50247997
63. S4646
64. Akos015994702
65. Ac-1330
66. Ccg-269962
67. Db01410
68. Ncgc00167972-01
69. Pregna-1,4-diene-3,20-dione, 16,17-(((r)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-
70. Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(r))-
71. Ciclesonide 100 Microg/ml In Acetonitrile
72. C3701
73. Cas-141845-82-1
74. C72110
75. D01703
76. 544c476
77. A899067
78. Sr-01000942227
79. Q5119448
80. Sr-01000942227-1
81. Ciclesonide, European Pharmacopoeia (ep) Reference Standard
82. (11?,16?)-16,17-[[(r)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione
83. 2-((6ar,6bs,7s,8as,8bs,10r,11ar,12as,12bs)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bh-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl Isobutyrate
84. 2h-naphth (2',1':4,5) Indeno (1,2-d) (1,3) Dioxole, Pregna-1,4-diene-3,20-dione Deriv.
85. Pregna-1,4-diene-3,20-dione, 16,17-(((r)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11.beta.,16.alpha.)
1. Desisobutyrylciclesonide
2. Desisobuytyryl Ciclesonide
3. Desisobutyryl Ciclesonide
| Molecular Weight | 540.7 g/mol |
|---|---|
| Molecular Formula | C32H44O7 |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 540.30870374 g/mol |
| Monoisotopic Mass | 540.30870374 g/mol |
| Topological Polar Surface Area | 99.1 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Alvesco |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of ALVESCO 80 mcg Inhalation Aerosol, and ALVESCO 160 mcg Inhalation Aerosol is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna-1,4-diene-3,20-dione, 16,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydr... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.08mg/inh; 0.16mg/inh |
| Market Status | Prescription |
| Company | Takeda Gmbh |
| 2 of 6 | |
|---|---|
| Drug Name | Omnaris |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of OMNARIS Nasal Spray is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna -1,4-diene-3,20-dione, 16,17-[[R-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-,(11,16)-. Ciclesoni... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Spray, metered; Spray |
| Route | nasal; Nasal |
| Strength | 50mcg; 0.05mg/inh |
| Market Status | Prescription |
| Company | Nycomed Us; Takeda Gmbh |
| 3 of 6 | |
|---|---|
| Drug Name | Zetonna |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of ZETONNA Nasal Aerosol is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna -1,4-diene-3,20-dione, 16,17-[[R-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-,(11,16)-. Cicleso... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Aerosol, metered |
| Route | Nasal |
| Strength | 0.037mg/inh |
| Market Status | Prescription |
| Company | Takeda Gmbh |
| 4 of 6 | |
|---|---|
| Drug Name | Alvesco |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of ALVESCO 80 mcg Inhalation Aerosol, and ALVESCO 160 mcg Inhalation Aerosol is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna-1,4-diene-3,20-dione, 16,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydr... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Aerosol, metered |
| Route | Inhalation |
| Strength | 0.08mg/inh; 0.16mg/inh |
| Market Status | Prescription |
| Company | Takeda Gmbh |
| 5 of 6 | |
|---|---|
| Drug Name | Omnaris |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of OMNARIS Nasal Spray is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna -1,4-diene-3,20-dione, 16,17-[[R-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-,(11,16)-. Ciclesoni... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Spray, metered; Spray |
| Route | nasal; Nasal |
| Strength | 50mcg; 0.05mg/inh |
| Market Status | Prescription |
| Company | Nycomed Us; Takeda Gmbh |
| 6 of 6 | |
|---|---|
| Drug Name | Zetonna |
| PubMed Health | Ciclesonide |
| Drug Classes | Anti-Inflammatory, Endocrine-Metabolic Agent |
| Drug Label | The active component of ZETONNA Nasal Aerosol is ciclesonide, a non-halogenated glucocorticoid having the chemical name pregna -1,4-diene-3,20-dione, 16,17-[[R-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-,(11,16)-. Cicleso... |
| Active Ingredient | Ciclesonide |
| Dosage Form | Aerosol, metered |
| Route | Nasal |
| Strength | 0.037mg/inh |
| Market Status | Prescription |
| Company | Takeda Gmbh |
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction (RAO), Summer Pasture Associated Recurrent Airway Obstruction (SPA-RAO)).
Ciclesonide is a pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120 times higher than the parent compound. The precise mechanism through which ciclesonide affects allergic rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic inflammation.
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
QR03BA08
R - Respiratory system
R01 - Nasal preparations
R01A - Decongestants and other nasal preparations for topical use
R01AD - Corticosteroids
R01AD13 - Ciclesonide
R - Respiratory system
R03 - Drugs for obstructive airway diseases
R03B - Other drugs for obstructive airway diseases, inhalants
R03BA - Glucocorticoids
R03BA08 - Ciclesonide
Absorption
Ciclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism. The intranasal administration of ciclesonide at recommended doses results in negligible serum concentrations of ciclesonide.
Clearance
152 L/hr [Following IV administration of 800 mcg of ciclesonide]
Des-ciclesonide undergoes metabolism in the liver to additional metabolites mainly by the cytochrome P450 (CYP) 3A4 isozyme and to a lesser extent by CYP 2D6.
Glucocorticoids such as ciclesonide can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Ciclesonide reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Ciclesonide is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Market Place
